reported in the CAPSTONE-1 Phase III study: adebrelimab (PD-L1 inhibitors) combined with carboplatin and etoposide as first-line treatment for ES-SCLC, extended the median OS from 10.8 months (chemotherapy group) to 15.3 months; HR = 0.72 (95% CI 0.58 - 0.90; P = 0.004) (17). Here, CD274 is linked to small cell lung carcinoma.